



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY

Sarcopenia as a predictor of prognosis and risk of recurrence in patients following curative treatment for hepatocellular carcinoma

Thesis

*A Study Submitted for the Partial Fulfillment of the
Master Degree in tropical department*

By

Mohamed Taha Hassan El-Sadaney
M.B.B.Ch

Under the Supervision of

Assist. Prof. Dr. / Ashraf Mohammad Mahmoud AlBreedy

*Professor of Tropical Diseases
Faculty of Medicine - Ain Shams University*

Dr / Manar Mohamed Salah el-din.

*Lecturer of Tropical Diseases
Faculty of Medicine - Ain Shams University*

**Faculty of Medicine
Ain Shams University
2021**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدقة الله العظيم

سورة البقرة الآية: ٣٢



*First, thanks are all due to **Allah** for Blessing this work until it has reached its end, as a part of his generous help throughout our life.*

Thanks to almighty Allah for giving me courage, health and strength to understand, learn and patience to complete this study successfully. Thanks for giving me the opportunities and skills to increase my small knowledge and experience. Peace and prayers to be upon his final messenger Muhammad, the ideal role model for all human beings.

*First and foremost, I would like to express my deepest sense of gratitude to **Professor Dr. Ashraf Mohammad Mahmoud AlBready**, Professor of Tropical Medicine Ain Shams University, who has the attitude and the substance of a genius. I am sincerely grateful to his devotion to his students' education and success owes him a huge debt of gratitude for his guidance, endless support and immense knowledge.*

*It is my genuine pleasure to express my heartiest thanks to **Dr. Manar Mohamed Salah El-din**, Lecturer of Tropical Medicine Ain Shams University for her kindness fruitful opinions, indispensable assistance, valuable guidance, support and encouragement throughout writing this thesis.*

Finally, I am profoundly indebted to my beloved mother and wife for their unconditional love, support and continuous encouragement throughout the whole long way. I would like to dedicate this work to them and to the spirit of my dear father.

Mohamed Taha Hassan El-Sadaney

List of Contents

	Page
List of Abbreviations	i
List of Tables	iii
List of Figures	iv
Abstract	v
 Introduction	1
Aim of the Work	3
 Review of Literature	4
Hepatocellular Carcinoma	4
• Etiology:	4
• Diagnosis of Hepatocellular Carcinoma:	12
• Staging Systems for Hepatocellular Carcinoma:	17
• Treatment of Hepatocellular Carcinoma	20
Sarcopenia	22
• Pathophysiology and impact of exercise training	33
• Sarcopenia and liver cirrhosis	35
• Possible mechanisms of sarcopenia in cirrhotic patients	36
• Sarcopenia and malignancy	38
• Diagnosis of sarcopenia	40
 Methodology	47
Results	54
Discussion	60
Summary	71
Conclusion	73
Recommendation	74
References	75
Arabic summary	--

List of Abbreviations

AASLD	: American Association for the Study of Liver Diseases.
AFP	: Alpha-fetoprotein.
AIDS	: Acquired immunodeficiency syndrome.
APHE	: Arterial phase hyper-enhancement.
ASCO	: American Society of Clinical Oncology.
BCLC	: Barcelona Clinic Liver Cancer.
BIA	: Bioelectrical impedance analysis.
BMI	: Body mass index.
Ca⁺²	: Calcium.
CKD	: Chronic kidney disease.
CLIP	: Cancer of liver Italian program.
CSA	: Cross sectional area.
CSPH	: Clinically significant portal hypertension.
CT	: Computed tomography.
DEB	: Drug eluting beads.
DEXA	: Dual energy X-ray absorptiometry.
DFS	: Disease free survival.
DM	: Diabetes mellitus.
EASL	: European Association for the Study of the liver.
ECOG	: The Eastern Cooperative Oncology Group.
EORTC	: European Organization for Research and Treatment of Cancer.
ER	: Endoplasmic reticulum.
FDA	: Food and Drug Administration.
FGF	: Fibroblast growth factor.
HbeAg	: Hepatitis B e antigen.
HBV	: Hepatitis B virus.
HCC	: Hepatocellular.
HCV	: Hepatitis C virus.
HH	: Hereditary hemochromatosis.
HIV	: Human immunodeficiency virus.
HR	: Hazard ratio.
IARC	: International agency for research on cancer.
IGF-1	: Insulin-like growth factor 1.
LC	: Liver cirrhosis.

LR	: Liver resection.
LT	: Liver transplantation.
MAMC	: Mid-arm muscle circumference.
MDCT	: Multidetector Computed tomography.
MELD	: Model for end-stage liver disease.
mRECIST	: Modified response evaluation criteria in solid tumor.
MRI	: Magnetic resonance imaging.
MWA	: Microwave ablation.
NAA	: Neutron Activation.
NAFLD	: Non-alcoholic fatty liver disease.
NASH	: Nonalcoholic steatohepatitis.
OS	: Overall survival.
PBC	: Primary biliary cirrhosis
PDGF	: Platelet derived growth factor.
PIF	: Proteolysis inducing factor.
PLA	: Percutaneous laser ablation.
PVA	: Polyvinyl alcohol.
RFA	: Radiofrequency ablation.
RFM	: Rectus femoris muscle.
SD	: Standard deviation.
SE	: Standard error.
SIRT	: Selective Internal Radiation Therapy.
SMI	: Skeletal muscle index.
SPSS	: Statistical package for the social science.
TACE	: Trans Arterial Chemoembolization.
TARE	: Trans Arterial Radioembolization.
TNF	: Tumor necrosis factor.
TNM	: Cancer's tumor-node-metastasis.
TPMT	: Transverse psoas muscle thickness.
TSF	: Triceps skinfold thickness.
TTP	: Time-to-progression.
UPS	: Ubiquitin proteasome-dependent system.
US	: Ultrasonography.
VEGF	: Vascular endothelial growth factor.
VEGFR	: Vascular endothelial growth factor receptor.
WD	: Wilson's disease.
α1AT	: Alpha1-antitrypsin

List of Tables

Table	Title	Page
(1)	Non-viral cirrhosis-related factors and environmental factors that can lead to the development of HCC.	12
(2)	Characteristics of 100 patients with HCC who underwent curative treatment.	54
(3)	Baseline characteristics in studied groups.	55
(4)	Comparison of overall survival between sarcopenic and non-sarcopenic patients.	56
(5)	Comparison between disease free survivals in both groups.	57
(6)	Results of cox regression for detection the predictors of poor survival.	58
(7)	Results of cox regression for detection the predictors for recurrence.	59

List of Figures

Fig.	Title	Page
(1)	Diagnostic algorithm and recall policy in cirrhotic liver.	17
(2)	Modified BCLC staging system and treatment strategy .	19
(3)	Multi-parametric assessment of the risk of liver decompensation after LR for HCC in cirrhosis.	24
(4)	Pathophysiology of sarcopenia.	33
(5)	Overview of the causes of sarcopenia in cirrhosis.	36
(6)	Comparison of overall survival between sarcopenic and non-sarcopenic patients.	56
(7)	Comparison between disease free survivals in both groups.	57

ABSTRACT

Purpose: This study is designed to evaluate the prognostic value of sarcopenia as a predictive method for survival of patients with hepatocellular carcinoma (HCC) who will receive curative treatment.

Methods: To determine the influence of sarcopenia on prognosis, skeletal muscle index (SMI) was measured using computed tomography at the level of the third lumbar vertebra of 100 patients who underwent radiofrequency for hepatocellular carcinoma (HCC). They were followed up for at least 7 months and overall survival and recurrence were identified. We defined sarcopenia using cutoff values for SMI as less than $43.75\text{cm}^2/\text{m}^2$ for men and $41.10\text{cm}^2/\text{m}^2$ for women.

Results: Sarcopenia was present in 54 of 100 patients and correlated significantly with low body mass index (BMI) and DM. Sarcopenia and MELD Na score were significantly associated with poor survival of the patients.

Conclusions: The study concluded that sarcopenia seemed to have a negative impact on OS in patients with HCCs. Sarcopenia could significantly increase the incidence rates of post-treatment recurrence and overall complications in patients with HCCs.

Keywords: hepatocellular carcinoma; skeletal muscle depletion; sarcopenia; prognostic factor

Introduction

According to the World Health Organization, HCC is the fifth most common tumor worldwide and the second most common cause of cancer-related death (*Heimbach et al., 2018*). Typically, patients with HCC have a poor clinical course as the prognosis is strongly affected by liver function and clinical cancer stage.

Among patients with cirrhosis, the cumulative 5-year risk of developing HCC ranges from 5% to 30%, depending on the presence and stage of underlying liver disease, age, sex and duration of the exposure to primary hepatotropic viruses (*El-Serag and Davila, 2011*).

The recurrence rate of HCC is extremely high in compare with other malignancies (*Tabrizian et al., 2015*) which is also associated with the poor prognosis.

Because of these peculiarities, the long-term prognosis for patients with HCC is very poor and the outcome prediction for this malignancy is extremely complicated. Therefore, it is important to identify useful prognostic factors for HCC in order to determine the best therapeutic approach in each case. Several prognostic staging systems, such as Barcelona Clinic Liver Cancer (BCLC), and Cancer of the Liver Italian Program (CLIP), most of which take both clinical cancer stage and liver

functional reserve into consideration, have been developed (*Llovet et al., 1999*).

Recently, skeletal muscle depletion or sarcopenia, defined as are low muscle mass with low muscle strength or physical performance, has earned attention as a new and promising prognostic factor for various malignancies such as pancreatic cancer, melanoma and lymphoma (*Sabel et al., 2011*). While HCC in contrast, remains unclear whether sarcopenia predicts prognosis and recurrence among patients with HCC who either undergo curative treatment or not. Skeletal muscle volume depletion assessed by computed tomography (CT) predicts poor prognosis of all cancer stage.

Aim of the Work

The aim of this study is to determine the prognostic value of sarcopenia as a predictive method for survival of patients with hepatocellular carcinoma (HCC) who will receive curative treatment.